Achieve Life Sciences, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on August 14, 2026, establishing an at-the-market equity offering program allowing the sale of up to $150.0 million in common stock. Jefferies will act as sales agent and receive compensation of up to 3.0% of gross proceeds. The company intends to use net proceeds for the commercialization of cytisinicline, funding a Phase 3 clinical trial for e-cigarette cessation, and general corporate purposes. Achieve Life Sciences operates in the biotechnology industry, focusing on developing treatments for addiction.

Achieve Life Sciences reported a net loss of $74.8 million for Q2 2026, driven by a $48.7 million non-cash charge from warrant liability revaluation and increased G&A expenses to $14.6 million. The company closed a private placement raising up to $354 million, including $180 million upfront and warrants exercisable upon FDA approval of cytisinicline. Achieve received a Complete Response Letter for its NDA due to cGMP manufacturing observations at a prior facility; it has transitioned production to Adare Pharma Solutions in the U.S. and plans an NDA resubmission in Q4 2026, targeting potential FDA approval in H1 2027. The firm appointed Andrew D. Goldberg as CEO and added six new board members alongside senior commercial and quality leadership. Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence.

Achieve Life Sciences, Inc. stockholders at the July 2, 2026, Annual Meeting approved a Certificate of Amendment to the Certificate of Incorporation to increase the number of authorized common stock shares from 150,000,000 to 300,000,000. The meeting also resulted in the election of nine directors to the board of directors and the following: PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year 2026. Achieve Life Sciences, Inc. is a life sciences company that develops and commercializes commercial-stage drugs for the treatment of addiction-related disorders.